Stanford University
Showing 21-40 of 80 Results
-
Bita Fakhri, MD, MPH
Assistant Professor of Medicine (Hematology)
BioDr. Bita Fakhri is Assistant Professor of Medicine in the Division of Hematology at Stanford University School of Medicine. She specializes in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), hairy cell leukemia, and other hematologic malignancies. As a clinical scientist, Dr. Fakhri is dedicated to caring for patients, teaching trainees, and researching novel therapies for patients with CLL/SLL. Dr. Fakhri has co-authored numerous publications on topics including CLL, novel targeted agents, and cellular therapies for patients with hematologic malignancies. Currently, Dr. Fakhri is the director of the CLL clinical trial portfolio at Stanford. Additionally, in her role as the DEI ambassador of the Division of Hematology, her main focus is to enhance trial equity among underserved and marginalized populations in the Stanford catchment area.
-
Jason Gotlib
Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:
--Myelodysplastic syndromes (MDS)
--Chronic myelogenous leukemia (CML)
--Acute myelogenous leukemia (AML)
--Myeloproliferative disorders (MPDs) including:
Hypereosinophilic syndrome
Systemic mastocytosis
BCR-ABL-negative MPDs -
Peter Greenberg
Professor of Medicine (Hematology), Emeritus
Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.
-
Ruwan Gunaratne
Instructor, Medicine - Hematology
BioRuwan Gunaratne, MD, PhD is an Instructor in Hematology at Stanford University School of Medicine and a board-certified hematologist-oncologist with a clinical focus on acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs). His clinical and translational research centers on improving disease monitoring in myeloid cancers using personalized circulating tumor DNA (ctDNA) profiling, a blood-based approach designed to more sensitively track measurable residual disease (MRD), assess treatment response, refine risk stratification, and detect relapse earlier across the myeloid disease spectrum. Dr. Gunaratne’s work has been recognized with awards from the American Society of Hematology and the Stanford Cancer Institute, and he is actively committed to advancing precision medicine approaches for patients with myeloid malignancies.
-
Florian Hoffmann, Ph.D.
Postdoctoral Scholar, Hematology
BioFlorian is a postdoctoral researcher in Dr. Ami Bhatt's laboratory at Stanford University. He earned his Ph.D. in Biochemistry working in Dr. Sam Sternberg's group at Columbia University where he studied atypical CRISPR systems in prokaryotes, in search of molecular tools for programmable gene editing and gene regulation. His studies elucidate the mechanisms of a novel RNA-guided transposition system, the evolutionary ancestors of the gene editing enzymes Cas9 and Cas12, and an unprecedented Cas12f enzyme that creates custom de novo transcription start sites without requiring promoter elements. Florian is fascinated by the vast untapped resources of novel gene functions encoded in bacteria and their viruses (bacteriophages). During his postdoctoral work at Stanford, he aims to discover novel paradigms of bacteria-virus interactions and how these shape the human gut microbiome, and human health. To investigate these systems, he harnesses interdisciplinary approaches, combining computational gene discovery with experimental techniques in Molecular Biology, Genetics and Biochemistry.
-
David Iberri
Clinical Associate Professor, Medicine - Hematology
BioDr. Iberri is a hematologist who specializes in the treatment of multiple myeloma, Waldenström macroglobulinemia, and other blood and bone marrow disorders. He is actively involved in clinical research evaluating novel agents in hematologic malignancies. His research interests include the development and application of biomarkers to select patients most likely to benefit from therapy, and in the development of blood tests to reduce the need for bone marrow biopsies in myeloma disease monitoring.
-
Thulasee Jose
Affiliate, Department Funds
Fellow in Medicine - Med/HematologyBioFellow - Hematology & Medical Oncology ( Pathway Research Track)
-
Calvin Kuo
Maureen Lyles D'Ambrogio Professor
Current Research and Scholarly InterestsWe study cancer biology, intestinal stem cells (ISC), and angiogenesis. We use primary organoid cultures of diverse tissues and tumor biopsies for immunotherapy modeling, oncogene functional screening and stem cell biology. Angiogenesis projects include blood-brain barrier regulation, stroke therapeutics and anti-angiogenic cancer therapy. ISC projects apply organoid culture and ko mice to injury-inducible vs homeostatic stem cells and symmetric division mechanisms.
-
Lawrence Leung
Maureen Lyles D'Ambrogio Professor in the School of Medicine
Current Research and Scholarly InterestsOur long term interest is to have a better understanding of the natural antithrombotic pathways and the pathophysiology of vascular thrombosis. We have focused on thrombin, the key enzyme in the blood clotting cascade.Our goal is to develop new antithrombotic agents and devise new diagnostic tests for vascular thrombotic disorders.
